R
0.024
0.00 (4.35%)
| Previous Close | 0.023 |
| Open | 0.023 |
| Volume | 828,490 |
| Avg. Volume (3M) | 3,641,945 |
| Market Cap | 56,015,520 |
| Price / Sales | 14.91 |
| Price / Book | 0.970 |
| 52 Weeks Range |
| Operating Margin (TTM) | -812.58% |
| Diluted EPS (TTM) | -0.060 |
| Quarterly Revenue Growth (YOY) | -40.00% |
| Current Ratio (MRQ) | 3.37 |
| Operating Cash Flow (TTM) | -33.42 M |
| Levered Free Cash Flow (TTM) | -16.48 M |
| Return on Assets (TTM) | -28.95% |
| Return on Equity (TTM) | -112.21% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (AU) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | RADIOPHARM FPO [RAD] | - | - |
AIStockmoo Score
0.3
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Average | 0.25 |
|
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 25.23% |
| % Held by Institutions | 15.91% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |